Jock C Lillard1, Garrett T Venable2, Nickalus R Khan2, Ruth G Tatevossian3, James Dalton3, Brandy N Vaughn4, Paul Klimo2,4,5. 1. College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee. 2. Department of Neurosurgery, University of Tennessee Health Science Center, Memphis, Tennessee. 3. Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee. 4. Le Bonheur Children's Hospital, Memphis, Tennessee. 5. Semmes Murphey, Memphis, Tennessee.
Abstract
BACKGROUND: Pediatric supratentorial ependymomas (SEs) have distinct molecular and behavioral differences from their infratentorial counterparts. OBJECTIVE: To present our experience with pediatric SEs over a 24-yr period. METHODS: Clinical, operative, and radiographic information was abstracted retrospectively. Our primary outcomes were progression-free survival (PFS) and overall survival (OS). Detection of C11orf95-RELA rearrangement was performed using interphase fluorescence in situ hybridization (iFISH). RESULTS: Seventy-three patients were identified (41 female, 32 male); median age was 6.7 yrs (range, 1 mo-18.8 yr); median follow-up was 8.3 yrs (range, 2.0-26.3). Fifty-eight (79.5%) of 73 patients underwent gross total resection (GTR); no patient with subtotal resection had greater than 1 cm3 of residual tumor; 42 patients (57.5%) experienced subsequent disease progression with 17 patients ultimately dying of their disease. Median PFS was 3.7 yrs. Molecular analysis was available for 51 patients (70%). On bivariate analysis, PFS and OS were not statistically affected by age, tumor grade, or extent of resection, although there was a clinically significant trend for the latter in favor of aggressive resection on PFS (P = .061). Children with RELA fusion had significantly higher PFS (P = .013) than those without, although there was no difference in OS when compared with those with no C11orf95-RELA fusion or C11orf95 gene rearrangement alone. CONCLUSION: In our series, GTR may be associated with better PFS, but did not impact OS. Surprisingly, RELA fusion was not found to be a negative prognostic factor, raising the possibility that the deleterious effects may be overcome by aggressive resection.
BACKGROUND: Pediatric supratentorial ependymomas (SEs) have distinct molecular and behavioral differences from their infratentorial counterparts. OBJECTIVE: To present our experience with pediatric SEs over a 24-yr period. METHODS: Clinical, operative, and radiographic information was abstracted retrospectively. Our primary outcomes were progression-free survival (PFS) and overall survival (OS). Detection of C11orf95-RELA rearrangement was performed using interphase fluorescence in situ hybridization (iFISH). RESULTS: Seventy-three patients were identified (41 female, 32 male); median age was 6.7 yrs (range, 1 mo-18.8 yr); median follow-up was 8.3 yrs (range, 2.0-26.3). Fifty-eight (79.5%) of 73 patients underwent gross total resection (GTR); no patient with subtotal resection had greater than 1 cm3 of residual tumor; 42 patients (57.5%) experienced subsequent disease progression with 17 patients ultimately dying of their disease. Median PFS was 3.7 yrs. Molecular analysis was available for 51 patients (70%). On bivariate analysis, PFS and OS were not statistically affected by age, tumor grade, or extent of resection, although there was a clinically significant trend for the latter in favor of aggressive resection on PFS (P = .061). Children with RELA fusion had significantly higher PFS (P = .013) than those without, although there was no difference in OS when compared with those with no C11orf95-RELA fusion or C11orf95 gene rearrangement alone. CONCLUSION: In our series, GTR may be associated with better PFS, but did not impact OS. Surprisingly, RELA fusion was not found to be a negative prognostic factor, raising the possibility that the deleterious effects may be overcome by aggressive resection.
Authors: M Zhang; L Tam; J Wright; M Mohammadzadeh; M Han; E Chen; M Wagner; J Nemalka; H Lai; A Eghbal; C Y Ho; R M Lober; S H Cheshier; N A Vitanza; G A Grant; L M Prolo; K W Yeom; A Jaju Journal: AJNR Am J Neuroradiol Date: 2022-03-31 Impact factor: 3.825
Authors: Joshua A Cuoco; Andrew C Strohman; Brittany M Stopa; Michael S Stump; John J Entwistle; Mark R Witcher; Adeolu L Olasunkanmi Journal: Rare Tumors Date: 2022-07-08